The U.S. Food and Drug Administration (FDA) has approved Pernix Therapeutics Holdings’ Treximet (sumatriptan and naproxen sodium) for use in pediatric patients 12 years of age and older for the acute treatment of migraine with or without aura. Treximet is the first approved combination prescription medicine, and the first to contain sumatriptan, for the treatment of acute migraine attacks in pediatric patients. The two medicines—sumatriptan and naproxen sodium—in combination provide more effe...